Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia. Fu Q, Wang Y, Liu H, Gao H, et al. Leuk Res 2024;145:107564.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fu Q, Wang Y, Liu H, Gao H, et al. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia. Leuk Res 2024;145:107564.
PMID: 39180903